Samuel D. Waksal and Erbitux

Samuel D. Waksal, founder of ImClone Systems, with vials of his company's cancer drug Erbitux. Stewart sold almost 4,000 shares of biotech drug maker ImClone a day before the U.S. Food and Drug Administration announced it will not review ImClone's application for Erbitux. Doctors in June 2003 concluded Erbitux worked just as well as an earlier company-sponsored study said it did.

( The New York Times / December 28, 2001 )

Samuel D. Waksal, founder of ImClone Systems, with vials of his company's cancer drug Erbitux. Stewart sold almost 4,000 shares of biotech drug maker ImClone a day before the U.S. Food and Drug Administration announced it will not review ImClone's application for Erbitux. Doctors in June 2003 concluded Erbitux worked just as well as an earlier company-sponsored study said it did.

  • Email E-mail
  • add to Twitter Twitter
  • add to Facebook Facebook
  • Home Delivery Home Delivery
Around the web Posts from business, finance and tech bloggers
>> Submit a blog: Give your favorite voices exposure
New cars for 2015

New cars for 2015

Dealers are cutting prices on 2014 models to make room for 2015 models, many of which go on sale this summer. Here's a look at redesigned or...

Nielsen names 14 breakthrough consumer products

14 breakthrough consumer products

Here is market research company Nielsen's list of 14 breakthrough consumer innovation products, based on products introduced in 2012 that...

Which stores have recently opened or closed in the Baltimore region?

Which stores have recently opened or closed in Baltimore?

Keep up with the latest news about store openings and closings in the Baltimore area.

Who are Maryland's billionaires?

Who are Maryland's billionaires?

Forbes magazine has released its annual list of international billionaires --1,645 people with an aggregate net worth of $6.4 trillion as of...

PHOTO GALLERIES